Tinzaparin safety and efficacy in pregnancy
- 265 Downloads
Unfractionated heparin has largely been replaced by low molecular weight heparin in the treatment and prevention of thrombosis and recurrent miscarriage in pregnancy. There is little information, however, about the efficacy and safety of tinzaparin, which has the advantage of being administered as a single daily dose.
To evaluate the safety and efficacy of tinzaparin use in pregnancy.
We retrospectively reviewed the medical records of women who were prescribed tinzaparin during pregnancy and the puerperium in our hospitals from January 2000 to December 2008. Tinzaparin was given as a single daily prophylactic dose for women with a history of venous thromboembolism (VTE) or recurrent miscarriage and as a single daily therapeutic dose for women diagnosed with VTE. The primary outcomes recorded were thrombosis, bleeding, allergy and thrombocytopenia.
One hundred and forty-nine women aged between 17 and 44 years received tinzaparin in pregnancy and the puerperium over the study period. The dose administered was therapeutic in 21 (14 %) cases and prophylactic in all others. VTE recurred in three women who had a history of VTE (3.6 %). Antepartum and postpartum haemorrhage occurred in 9.7 and 5 % of cases, respectively and two women developed thrombocytopenia but their platelets remained above 100,000/ml. Fifty-seven women (38 %) had regional anaesthesia without complication.
Our study demonstrates a safety profile for tinzaparin in pregnancy that is equivalent to other low molecular weight heparins with the advantage of single daily dosing.
KeywordsTinzaparin Anticoagulation Venous thromboembolism Pregnancy
Conflict of interest
- 2.Centre for Maternal and Child Enquiries (CMACE) (2011) Saving Mothers’ Lives: reviewing maternal deaths to make motherhood safer: 2006–08. The Eighth Report on Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 118 (Suppl 1):1–203Google Scholar
- 3.Chang J, Elam-Evans LD, Berg CJ et al. (2003) Pregnancy-related mortality surveillance-United States, 1991–1999. MMWR Surveill Summ 52(2):1–8Google Scholar
- 6.Bates SM, Greer IA, Middeldorp S et al (2012) (2012) Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl 2):e691S–e736SPubMedCentralPubMedGoogle Scholar
- 7.Van Dongen CJ, van den Belt AG, Prins MH et al. (2004) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (4):CD001100. ReviewGoogle Scholar
- 8.Sanson BJ, Lensing AWA, Prins MH et al (1999) Safety of LMWH in pregnancy: a systematic review. ThrombHaemost 81:668–672Google Scholar
- 9.Royal College of Obstetrics and Gynaecology Green Top Guideline Number 37Google Scholar
- 14.Thromboprophylaxis During Pregnancy, Labour and after Vaginal Delivery. GreenTop Guideline 37Google Scholar